NCT06672523View on ClinicalTrials.gov

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

PHASE1RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 24, 2025

Primary Completion Date

April 20, 2026

Study Completion Date

April 20, 2026

Conditions
Advanced Solid Tumors With Homozygous MTAP Deletion
Interventions
DRUG

BMS-986504

Specified dose on specified days

DRUG

[14C]-BMS-986504

Specified dose on specified days

Trial Locations (1)

1076

RECRUITING

ICON / PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06672523 - A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion | Biotech Hunter | Biotech Hunter